OTSUKA PHARMACEUTICAL CO., LTD.

Otsuka submitted an NDA to Japan's Ministry of Health for bempedoic acid, a novel cholesterol treatment, after a Phase 3 trial showed significant LDL-C reduction in statin-intolerant patients. Esperion, the developer, expects this to be a new option for hypercholesterolemic patients.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen time. OTC products lead, with prescription therapies underutilized. Market challenges include product tolerability issues and regulatory hurdles. Innovations and strategic initiatives by key players, like the FDA approval of Tyrvaya nasal spray, are boosting the market. North America leads due to high disease prevalence and treatment awareness.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen exposure. OTC products lead, with only 10% on prescription therapies. Innovations and new product launches by key players like Novartis, AbbVie, and Oyster Point Pharma are boosting the market.

Esperion Therapeutics reports $31.1M in product sales, $20.5M in collaboration revenue, and a net loss of $29.5M. The company focuses on oral, non-statin medicines for cardiovascular disease, with lead products NEXLETOL and NEXLIZET. Regulatory approvals and clinical trial results support product efficacy. Strategic initiatives include a royalty purchase agreement and capital management. Challenges include financial performance, market competition, and regulatory risks.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.

This study uses a matching-adjusted indirect comparison (MAIC) to explore the relative clinical efficacy and safety of difamilast versus delgocitinib in patients with atopic dermatitis (AD) in Japan. Both drugs have been proven efficacious and safe in phase 2 and 3 clinical trials, but no head-to-head trials have compared their efficacy and safety directly. The MAIC method aligns patient-level data from the difamilast trial with aggregate data from the delgocitinib trial, reducing bias in treatment comparisons. The study finds no notable statistical differences between the two treatments in terms of proportion of patients by severity, mean percentage change in mEASI at week 4, achievement of mEASI-50 and mEASI-75, and incidence of adverse events at week 4, suggesting comparable clinical efficacy and safety.

Otsuka Pharmaceutical and Bonafide Health launched 'Thermella™', a plant-based menopause supplement in the U.S., containing curcumin, decaffeinated green tea, and spirulina extracts, aiming to relieve hot flashes and night sweats.

Aurinia Pharmaceuticals announces Japanese approval of voclosporin, in combination with mycophenolate mofetil, for treating lupus nephritis, based on the AURORA Clinical Program data.